trastuzumab emtansine in her2 breast cancer
Published 3 years ago • 1.1K plays • Length 7:45Download video MP4
Download video MP3
Similar videos
-
6:40
her2 breast cancer: managing patients on t-dm1
-
6:35
treatment for high- and low-risk her2 breast cancer
-
5:59
trastuzumab deruxtecan for the treatment of her2 breast cancer
-
4:45
evolving role of her2-targeted therapy in breast cancer
-
3:51
adjuvant t-dm1 therapy for early-stage her2 breast cancer
-
6:53
treating early her2 breast cancer: katherine
-
0:59
sequencing her2-targeted therapies in breast cancer
-
8:42
trastuzumab deruxtecan in her2 breast cancer
-
5:39
improving long-term outcomes in her2 breast cancer
-
2:02
dr. pegram on early treatment with t-dm1
-
1:31
current treatment options for patients with her2-positive metastatic breast cancer
-
0:46
clinical trials remain underway for trastuzumab deruxtecan in her2-positive breast cancer
-
5:15
case review: t-dm1 for residual her2 breast cancer
-
5:46
adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for her2-positive breast cancer
-
2:25
reducing risk in residual breast cancer
-
3:48
neoadjuvant t-dm1 in early-stage her2 breast cancer
-
4:52
3-year dfs in randomized trials of chemotherapy and her2-targeted therapy
-
3:19
study of targeted therapy for her2-positive metastatic breast cancer
-
1:36
phase 3 trial investigates t-dm1 and pertuzumab in her2 breast cancer